What Is a Longevity Clinic? What Is Evidence-Based, What Is Marketing, and What to Ask

The screenshot arrived in a family group chat late on a Sunday: a friend’s “biological age” report, three years younger than her birthday, framed in a soft sage-green dashboard. Underneath it, a question that a lot of people are quietly typing into search bars: is a longevity clinic something a normal person should actually consider?

As of early 2026, that question is trending for a reason. Direct-to-consumer epigenetic age tests, whole-body MRI advertisements, wearable glucose sensors sold to people without diabetes, and social-media protocols built around drugs originally approved for transplant patients have all landed in the same year. Executive health programs that once quietly served corporate boards now market to anyone with a smartphone.

Some of what these clinics do is excellent preventive medicine, delivered with more time and attention than a 15-minute visit allows. Some of it is expensive theater. The trick is telling the two apart, and that is a skill you can learn in about twenty minutes of reading.

What does a longevity clinic actually do?

Strip away the branding and most longevity clinics deliver four things. First, a long intake: a physician or nurse practitioner spends 60 to 90 minutes on your family history, medications, sleep, exercise and stress. Second, a large laboratory panel, often 60 to 100 markers where a routine annual visit might run 15. Third, some combination of body-composition scanning, fitness testing and imaging. Fourth, a plan, usually with follow-up visits, coaching and, at some clinics, prescriptions aimed at slowing aging itself.

The vocabulary shifts from clinic to clinic. “Longevity medicine,” “precision medicine,” “functional medicine” and “executive health” overlap heavily. What they share is a focus on people who feel well and want to stay that way, which is a different job from treating disease. The reader should know one structural fact up front: in the United States there is no board certification in longevity medicine recognized by the American Board of Medical Specialties. The clinician you meet may be an internist, a cardiologist, an emergency physician or a family doctor who has taken continuing-education courses. That is not a criticism; it simply means the label tells you nothing about training, and you should ask.

The best programs behave like an unhurried internal medicine practice with a research habit. They measure the risk factors that decades of trials have shown matter, explain them clearly, and help you change them. The weaker programs lean on the parts of the menu with the thinnest evidence, because those are the parts that feel novel and justify a membership.

A useful mental model: geroscience, the study of how biological aging drives disease, is a real and active field. The National Institute on Aging funds it. But almost every intervention that has extended lifespan in mice is still at the stage of “promising in animals, unproven in people.” A clinic can honestly sell you excellent prevention today. It cannot honestly sell you slower aging tomorrow, because nobody has shown that in humans yet.

What changed recently to put longevity clinics in the spotlight

Several dated developments explain why searches for longevity clinics have climbed, and they are worth separating because they carry very different weights of evidence.

In June 2022 the American Heart Association updated its Life’s Simple 7 to Life’s Essential 8, adding sleep duration as a core cardiovascular health metric alongside diet, physical activity, nicotine exposure, weight, blood lipids, blood glucose and blood pressure. That update matters for this topic because it is, in effect, a peer-reviewed longevity checklist. Large observational cohorts show that adults scoring high on these eight measures live years longer and spend fewer of those years with cardiovascular disease.

On the pharmaceutical side, the NIA Interventions Testing Program, a multi-site mouse study run by the National Institute on Aging, first reported in 2009 that rapamycin extended lifespan in genetically diverse mice even when started late in life. That finding has been repeated and is one of the most robust results in aging biology. It is also the single most misquoted study in longevity marketing, because a mouse result is routinely presented as if it were a human one.

In 2023 a large randomized cardiovascular-safety trial of testosterone in men with diagnosed low testosterone reported no excess of major heart events over roughly two years of follow-up. Clinics have leaned on that result to reassure men. The trial answered a safety question in men with a diagnosed deficiency; it did not test whether testosterone helps healthy aging men live longer or better.

The consumer layer changed too. Epigenetic age tests became mail-order products. Whole-body MRI moved from academic research protocols to shopping-mall storefronts. Continuous glucose monitors, once prescription-only devices for diabetes, became available over the counter. Each of these is a genuine technology. None of them has a randomized trial showing that using it makes a healthy person live longer, and that gap is the whole story of this article.

What the evidence actually says, graded honestly

Medicine grades evidence in rough tiers. Randomized controlled trials, where people are assigned by chance to an intervention or a comparison, sit at the top. Observational studies, which follow people who happened to make different choices, sit below because healthier people tend to make healthier choices for reasons the study cannot fully capture. Expert opinion and mechanistic reasoning sit lower still. Here is how the longevity clinic menu sorts into those tiers.

Strong, randomized-trial evidence for reducing death or serious disease: treating high blood pressure; lowering LDL cholesterol in people at elevated risk; controlling blood glucose in diabetes; stopping smoking; recommended cancer screening such as colorectal screening starting at age 45 for average-risk adults and mammography from the 40s; vaccination against influenza, pneumococcal disease and shingles at the ages public-health agencies specify; and structured exercise programs, which in trials improve blood pressure, glucose, mood and physical function.

Strong observational evidence, consistent across many cohorts: cardiorespiratory fitness, often expressed as VO2 max, the maximum rate your body can use oxygen during exercise, is one of the strongest single predictors of mortality ever measured. Muscle strength, sleep of roughly seven to nine hours, Mediterranean-pattern eating and social connection all track with longer life. The associations are large and biologically plausible, but randomized trials on lifespan itself are mostly impractical.

Promising but unproven in humans: rapamycin, metformin for people without diabetes, NAD+ precursors, epigenetic age as a treatment target, and whole-body MRI as screening. Each has animal data, small human studies, or both. None has a human trial showing longer life or fewer deaths.

Weak or contradicted: intravenous vitamin infusions in people who eat normally; growth hormone for aging; most “detox” offerings; and high-dose antioxidant supplements, which in several large trials did not reduce mortality and in some cases increased it.

A clinic earns trust by spending most of its energy in the first two tiers and being candid about the third.

Longevity blood tests: which ones carry real evidence?

The phrase “longevity blood tests” covers a panel that ranges from indispensable to decorative. The indispensable core is short, and you can get most of it through an ordinary primary-care visit.

A standard lipid panel and hemoglobin A1c, a measure of average blood sugar over about three months, anchor cardiovascular and metabolic risk. Kidney function, liver enzymes, a complete blood count and thyroid-stimulating hormone round out the basics that guidelines already recommend at intervals based on age and risk.

Two additions have earned their place in many cardiology guidelines. Apolipoprotein B, or ApoB, counts the number of cholesterol-carrying particles that can lodge in artery walls, and in observational data it predicts heart attacks somewhat better than LDL cholesterol alone. Lipoprotein(a), or Lp(a), is a largely inherited particle that raises heart-attack and aortic-valve risk; several major cardiology societies now suggest measuring it once in adulthood because levels barely change over a lifetime. High-sensitivity C-reactive protein, a marker of low-grade inflammation, adds modest predictive value in intermediate-risk adults. These are reasonable tests. They are not exotic.

Further out on the panel you meet hormones, dozens of micronutrients, heavy metals, food-sensitivity IgG antibodies and “inflammatory cytokine panels.” Food-sensitivity IgG testing is not supported by allergy societies as a diagnostic tool. Broad micronutrient panels in people eating a varied diet mostly generate mild abnormalities of unclear meaning. Every borderline result creates a decision, and each decision carries a chance of an unnecessary treatment or a repeat test.

One number worth understanding: if a healthy person has 80 independent tests drawn, statistics alone predict about four will fall outside the “normal” range. A clinician who understands this will tell you which results changed the plan and which are noise. Ask that question directly: “Which of these results would you have acted on if we had only checked the standard panel?” The answer usually reveals how much of the extra testing was medicine and how much was menu.

Biological age tests and epigenetic clocks: do they mean anything?

An epigenetic clock is an algorithm that estimates age from chemical tags, called methylation marks, on DNA in a blood or saliva sample. The first widely cited version was published in 2013 and predicted chronological age with striking accuracy across tissues. Later versions were trained not on birthdays but on health outcomes, so that a higher “age” tracks with mortality risk in large cohorts.

That research is legitimate and interesting. The consumer product built on it has three problems.

The first is precision. Repeat the same test on the same sample and the estimate can shift by several years. A report telling you that you are 3.2 years “younger” may be measuring statistical wobble rather than biology, and a month-later retest showing improvement may reflect that same wobble in reverse.

The second is causation. Clocks were built to predict, not to be treated. No randomized trial has shown that lowering an epigenetic age score by any intervention translates into fewer heart attacks, cancers or deaths. A few small trials report that diet, exercise or specific drugs nudge the clock; whether that nudge means anything for the person is unknown. The marketing sentence “reverse your biological age” describes a change in a number, not a change in your future.

The third is actionability. Suppose the test says you are five years “older.” What changes? In practice the advice is the same prescription every reasonable clinician already gives: sleep, movement, blood pressure, lipids, glucose, not smoking. The test adds emotional weight to advice you already had.

There is a defensible use: research, and perhaps motivation for someone who responds to numbers. There is also a downside that rarely appears in the brochure. A person who receives an unexpectedly “old” result can carry anxiety for months about a figure that no clinician can act on. If you take one, treat it as a curiosity, not a diagnosis, and never let it override the standard risk factors your doctor can actually measure and modify.

Full-body MRI and whole-body scans: helpful or harmful?

Whole-body MRI uses magnetic fields rather than radiation to image the head, neck, chest, abdomen and pelvis in a single session, typically an hour or so. It is a remarkable technology. It is also, for a person with no symptoms and no elevated risk, a screening test with no randomized-trial evidence that it prevents deaths, and a well-documented tendency to find things that were never going to hurt you.

Radiologists call these incidental findings. Studies of whole-body imaging in asymptomatic adults report abnormalities in a large share of scans, often a third or more, the great majority benign: small cysts on the kidney or liver, tiny lung nodules, thyroid nodules, spinal changes that are simply what a 50-year-old spine looks like. Each finding tends to generate follow-up imaging, sometimes a biopsy, and always a period of worry. The medical term for this cascade is overdiagnosis, and it is the central reason no major screening guideline in the United States, United Kingdom or Europe recommends whole-body MRI for the general population.

The counterargument is the story of the one person whose early tumor was caught. Those stories are real. What the stories cannot tell you is how many people in the same clinic had unnecessary procedures, or whether the tumor found would have been caught in time by standard screening anyway. Screening is judged by populations, and by that measure the evidence is absent.

Targeted imaging is a different matter. A coronary artery calcium score, a low-dose CT scan that counts calcified plaque in heart arteries, is endorsed in cardiology guidelines to refine risk in adults at intermediate estimated risk, because a score of zero meaningfully lowers the odds of an event over the next decade. Low-dose lung CT is recommended for adults with a substantial smoking history in a specific age range. Those tests answer a defined question in a defined group. A whole-body scan answers no defined question, which is exactly why it feels reassuring and exactly why it is hard to defend.

Continuous glucose monitors, wearables and the data-optimization pitch

A continuous glucose monitor, or CGM, is a small sensor worn on the arm that reads glucose in the fluid under the skin every few minutes and sends it to a phone. For people with diabetes, especially those using insulin, randomized trials show CGMs improve glucose control and reduce dangerous lows. That is settled.

For people without diabetes, the evidence is nearly blank. Glucose rises after meals in everyone; that is what glucose is supposed to do. Healthy adults wearing CGMs routinely see readings that trigger app alerts yet fall within the normal physiological range. No trial has shown that a person without diabetes who wears a CGM lives longer, avoids diabetes or even sustains meaningful weight loss compared with someone who does not. What the devices reliably produce is engagement, and for a subset of people, a preoccupation with food that borders on disordered eating.

Wearables that track heart rate, sleep and step counts sit on slightly firmer ground. Step counts have good observational support: cohorts show mortality falling steadily as daily steps rise toward the 7,000 to 9,000 range, with diminishing returns beyond. Resting heart rate and heart-rate variability trend with fitness and stress, and consumer devices measure them reasonably well. Sleep staging on a wrist device is far less accurate than a sleep lab, so treat the “deep sleep” figures as entertainment.

A fair question to ask a longevity clinic is what it does with the stream. Data that changes a decision, say a wearable that flags an irregular heart rhythm later confirmed on an ECG, is medicine. Data that decorates a dashboard is not. A well-run clinic will tell you which wearable metrics it trusts, which it ignores, and why. A poorly run one will treat every number as actionable, and a person who is told that everything matters ends up unable to tell what does.

Rapamycin, metformin, NAD+ and peptides: what is the regulatory status?

This is the part of the longevity clinic menu most people are really asking about, so plain language matters.

Rapamycin (also called sirolimus) is approved in the United States for preventing organ-transplant rejection and for a rare lung condition. It works by inhibiting mTOR, a cellular growth-signaling pathway. In the NIA Interventions Testing Program it extended mouse lifespan reliably. Human data consist of small trials looking at immune markers and safety in older adults; none has measured lifespan or major disease outcomes. Prescribing it to a healthy person to slow aging is off-label use. Known side effects on its label include mouth ulcers, raised lipids and glucose, and increased infection risk. Whether the mouse benefit exists in people is unknown, and any prescribing decision belongs to the treating clinician after a discussion of that uncertainty.

Metformin is approved for type 2 diabetes. Observational studies once suggested people with diabetes taking it lived longer than expected, but later analyses attributed much of that to study design. A proposed randomized trial in people without diabetes, known as TAME, has been discussed for years and has not delivered results. Use for aging in people without diabetes is off-label and unproven.

NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide are forms of vitamin B3 chemistry. Small human trials show they raise NAD+ levels in blood. Trials measuring anything a patient would notice, such as strength, cognition or disease, are small and mixed. Their regulatory status as supplements has shifted over recent years; they are not approved drugs for aging.

Research peptides, a catch-all for compounds like BPC-157 and similar products sold online, are not approved for human use in the United States. They are labeled “for research only” precisely because they have not passed safety or efficacy review. They are not for sale as medicines and not for self-use, and a clinic offering them is operating outside approved medicine.

Compounded versions of any of these, made by pharmacies rather than manufacturers, do not carry the same testing as approved products. A clinic should be able to state, without hesitation, which of its prescriptions are approved for the purpose being proposed and which are not.

Hormone optimization: testosterone, growth hormone and what the trials show

Hormone levels change with age, and hormone therapy is where longevity clinics most often cross from prevention into treatment. The evidence differs sharply by hormone.

Testosterone is approved for men with hypogonadism, a diagnosed deficiency confirmed by repeated low morning blood levels plus symptoms. In that group, randomized trials show improvements in sexual function, modest gains in lean mass and bone density, and small effects on mood and energy. The 2023 cardiovascular-safety trial reassured on heart events over about two years, while noting higher rates of atrial fibrillation, blood clots in the lung and acute kidney injury in the treatment group. What no trial has shown is that giving testosterone to men with normal or borderline levels extends life, prevents disease or reverses aging. “Optimization” to a target in the upper range of normal is an opinion, not an evidence-based practice, and the decision to treat rests with a clinician who has confirmed a diagnosis.

Growth hormone is approved for children and adults with confirmed deficiency. In healthy older adults, small trials found increases in lean mass and decreases in fat mass but no improvement in strength or function, alongside fluid retention, joint pain, carpal tunnel symptoms and glucose intolerance. Endocrine societies advise against its use for aging. Prescribing it for that purpose is off-label and, in the United States, restricted by law to specific indications.

Menopausal hormone therapy is approved to treat menopause symptoms such as hot flashes and to prevent bone loss in appropriate women. Large randomized trials established both benefits and risks that depend on age at starting, time since menopause and formulation. It is a legitimate, guideline-supported treatment for symptoms. It is not a longevity intervention, and framing it as one misrepresents the trials.

The recurring pattern: hormones treat diagnosed deficiency or specific symptoms well, and that is exactly how the evidence supports using them. Extending the same treatment to healthy people in pursuit of youthful numbers has no outcome data behind it.

IV drips, supplements and the add-on menu

Walk past the consultation rooms in many longevity clinics and you reach a lounge of reclining chairs and IV poles. The offerings vary: vitamin C, B-complex, glutathione, magnesium, NAD+, “immune boost” and “recovery” blends. The evidence does not vary; for people who eat a reasonable diet and can absorb nutrients normally, there is no randomized trial showing that intravenous vitamins improve any health outcome. Water-soluble vitamins given in excess leave in urine within hours. The needle carries a small but real risk of infection and vein irritation, and any procedure done without a medical indication has a benefit of zero against which to weigh that risk.

Oral supplements are a more nuanced picture, and honest grading helps.

• Vitamin D: large randomized trials in generally healthy adults found no reduction in cancer, cardiovascular disease or fractures from supplementation. Correcting a documented deficiency remains sensible; blanket high-dose use is not supported.
• Omega-3 fish oil: results across trials are mixed; a benefit for cardiovascular events appears in some high-dose prescription-formulation trials but not in general-population supplement trials.
• Multivitamins: one large trial reported a modest slowing of cognitive decline over three years; mortality benefit has not been shown.
• Antioxidants such as high-dose vitamin E and beta-carotene: trials found no benefit and, in smokers, harm from beta-carotene.
• Creatine: good evidence for strength gains when combined with resistance training, especially in older adults.

The NIH Office of Dietary Supplements maintains fact sheets on each of these, written for both consumers and clinicians, and they are the neutral reference point a clinic should be able to match. A clinic that sells its own branded supplement line has a financial reason to recommend supplements, which is not disqualifying but is worth knowing. Ask whether any recommended product is one the clinic profits from, and ask what would change if you declined it. If the answer is “nothing much,” you have your answer.

Longevity clinic services compared: what is proven and what is promise

The table below summarizes the menu you are likely to encounter, the strength of the evidence for each item in otherwise healthy adults, and the question that separates a good use from a poor one. Evidence grades follow the tiers described earlier: randomized trials, observational data or expert opinion.

Service	Strongest evidence type	What it shows for healthy adults	Ask before agreeing
Blood pressure, lipid and glucose management	Randomized trials	Fewer heart attacks, strokes and deaths	Is my plan aligned with standard guidelines?
Guideline cancer screening (colon, breast, cervical, lung for smokers)	Randomized trials and large cohorts	Lower cancer death in eligible ages	Am I in the eligible age and risk group?
Fitness testing (VO2 max, grip strength)	Observational, very consistent	Strong prediction of mortality; trials show training improves function	Will results change my exercise plan?
ApoB, Lp(a), hs-CRP	Observational plus guideline endorsement	Refine cardiovascular risk	Would a result change treatment?
Coronary artery calcium score	Observational, guideline-endorsed for intermediate risk	Reclassifies risk up or down	Is my estimated risk in the intermediate range?
Epigenetic biological-age test	Observational; small trials on the score itself	Predicts risk in cohorts; no proof treating it helps	What decision depends on this number?
Whole-body MRI	No trials; case series	Frequent incidental findings; no mortality benefit shown	What happens if something ambiguous appears?
CGM without diabetes	No outcome trials	Data without proven benefit	What threshold would prompt action?
Rapamycin, metformin for aging	Animal trials; small human safety studies	Unproven in humans; off-label	Is this approved for my situation?
Hormone therapy without diagnosed deficiency	Trials in deficient patients only	No longevity benefit shown; known risks	Has a deficiency been confirmed twice?
IV vitamin infusions	None in nourished adults	No demonstrated benefit	What is the medical indication?

Read down the first two columns and the pattern is hard to miss. Everything with randomized-trial support is available in ordinary primary care. The clinic’s genuine added value lies in time, coordination and follow-through, which are real and often lacking elsewhere, not in the exotic rows.

Is a longevity clinic covered by insurance?

Usually not as a package, and understanding why clarifies what you would be paying for.

In the United States, health plans cover preventive services that carry a recommendation from national bodies: the periodic visit, blood pressure and cholesterol checks, diabetes screening in adults with risk factors, age-appropriate cancer screening, and vaccines on the adult schedule. Medicare offers an annual wellness visit that includes a risk assessment and a personalized prevention plan. All of that is ordinary preventive medicine, and it is the evidence-based core that a longevity clinic also provides.

What insurance does not cover is the layer on top: extended consultation time beyond standard visit codes, membership fees, panels of dozens of tests without a diagnosis to justify them, whole-body imaging, epigenetic age assays, IV infusions, off-label prescriptions for aging and concierge access. Clinics therefore typically operate on a cash or membership model, sometimes billing your insurance for the covered pieces and charging directly for the rest. Ask exactly how that split works before your first visit, because the answer is often more complicated than the website implies.

Outside the United States the structure differs. The NHS in England offers a free Health Check every five years to adults aged 40 to 74 without an existing cardiovascular diagnosis, measuring the same core risk factors a longevity clinic would. Private longevity services exist alongside it, paid out of pocket.

A useful reframing: the question is not really whether a clinic is “covered” but whether the uncovered portion buys you something the evidence values. Extended time with a thoughtful clinician who coordinates your screening, adjusts your blood pressure and lipid plan, and actually follows up in six weeks has real, if unglamorous, worth. Paying for a whole-body scan and an infusion lounge buys you a pleasant afternoon and an unquantified chance of a follow-up biopsy. Both come from the same menu. Only one is medicine.

Are longevity clinics worth it? An honest framework

Whether a longevity clinic is worth it depends less on the clinic than on what you would otherwise get, so start by auditing your current care.

If you already have a primary-care clinician who knows your history, keeps your blood pressure and cholesterol at target, reminds you of screening dates, and answers a message within a day, the incremental benefit of a longevity clinic is small. Your fitness, sleep and diet are your own to change, and no dashboard changes them for you.

If, like many adults, you see a different clinician each visit, have a blood pressure reading that nobody has addressed, are overdue for colorectal screening, and have never had your cardiovascular risk explained in numbers, then a well-run longevity clinic can deliver something valuable: the preventive care you were supposed to receive, with time attached. In that scenario the clinic is worth it for its ordinary parts.

The people for whom it is least likely to be worth it are, paradoxically, the ones the marketing targets most: healthy, fit, non-smoking adults in their 30s and 40s with normal labs. For that group, additional testing mostly finds noise, and the exotic interventions carry unproven benefit against known or unknown risk.

My own opinion, grounded in the evidence above, is that the most valuable thing a clinic can sell is a relationship with a clinician who will tell you no. No to the scan you do not need. No to the hormone you do not lack. No to the supplement stack, and yes to the strength training, the earlier bedtime and the blood pressure medicine you have been avoiding. Clinics that behave that way exist. They tend to be quieter about it than the ones that do not.

A reasonable test before committing: ask what the clinic would recommend for a healthy 45-year-old with normal labs. If the answer is a long list of purchases, the incentive structure is showing. If the answer is “probably very little beyond what you already know,” you have found a clinician worth paying to talk to.

Common myths about longevity clinics, corrected

Viral claims travel faster than trial results. These are the ones that come up most often, with what the evidence actually shows.

“Biological age tests tell you how long you will live.” They estimate a population-level risk marker with several years of measurement uncertainty. They do not predict an individual lifespan, and no trial shows that improving the score improves outcomes.

“Rapamycin has been shown to extend human life.” It has been shown to extend mouse life. Human studies are small and measure surrogate markers. The drug is approved for transplant patients and a rare lung disease, not for aging.

“A full-body scan catches cancer early, so it can only help.” Screening can harm through false alarms, unnecessary biopsies and treatment of tumors that would never have caused illness. That is why guideline bodies weigh benefit against harm and recommend targeted screening in specific age and risk groups rather than scanning everyone everywhere.

“More blood tests mean better prevention.” Beyond a well-chosen core panel, extra tests mainly add false positives. Roughly one in twenty independent results in a healthy person falls outside the reference range by chance alone.

“Hormone levels should be optimized to youthful ranges.” Hormone therapy is evidence-based for diagnosed deficiency and specific symptoms. Pushing normal levels higher has no outcome data and carries documented risks.

“IV vitamins are absorbed better, so they work better.” They are absorbed completely, and in nourished adults the excess is excreted within hours. Better absorption of something you do not lack is not a benefit.

“Longevity doctors are specialists.” There is no recognized specialty board. The clinician may be excellent; the title alone does not tell you.

“The wealthy know something the rest of us do not.” The interventions with the strongest evidence for a longer life are not secret and not expensive: not smoking, moving daily, keeping blood pressure and lipids controlled, sleeping enough, staying connected to other people, and showing up for recommended screening. Everything else is a hypothesis.

What to ask a longevity clinic before you sign up

A good clinic will welcome these questions. A weak one will find them irritating, which is itself an answer.

About the clinician. What is your board certification, and in which specialty? How much of your practice is preventive care versus treating illness? Who covers when you are away, and will they have my records?

About testing. For each test beyond a standard panel, what decision would it change? What is your plan when an incidental finding appears on imaging? How do you handle a result that is mildly abnormal but clinically meaningless?

About treatments. Which of the medicines you might recommend are approved for the purpose you are proposing, and which are off-label? What human trial data exist, not animal data? What are the known side effects on the label? Do you prescribe compounded products, and if so, why not the approved version?

About conflicts of interest. Does the clinic sell supplements, devices or tests that it also recommends? Do you receive payment from laboratories or imaging centers you refer to?

About coordination. Will you share results and plans with my existing primary-care clinician? How do you avoid duplicating tests or contradicting their advice? Who manages an abnormal finding: you, them or a specialist?

About outcomes. How do you measure whether your program works? Do you track blood pressure control, lipid targets, screening completion and fitness change across your patients, or only satisfaction? A clinic that cannot answer this is running on faith.

Bring your last set of labs and your medication list, and notice what the clinician does with them. Someone who studies your existing data before ordering new data is practicing medicine. Someone who orders the full panel before opening your chart is practicing retail. And keep your primary-care clinician in the loop regardless; every prescribing decision, including whether to start, change or stop anything, belongs to the person who knows your whole history and will still be there next year.

When to see a doctor: red flags that a longevity clinic should not delay

Longevity care is built for people who feel well. It is the wrong setting, and the wrong pace, for symptoms that need prompt evaluation. If any of the following apply, contact your regular clinician or seek urgent care rather than waiting for a scheduled wellness consultation.

• Chest pain or pressure, especially with exertion, breathlessness, sweating or pain spreading to the arm or jaw. Call emergency services.
• Sudden weakness or numbness on one side, facial drooping, slurred speech, sudden confusion or loss of vision. These are stroke warning signs and need emergency care immediately.
• Unexplained weight loss, persistent fever, night sweats or fatigue that does not improve with rest.
• Blood in stool or urine, black stools, or coughing up blood.
• A new lump, a mole that is changing, or a sore that does not heal.
• Persistent change in bowel habit, difficulty swallowing, or hoarseness lasting more than three weeks.
• Severe or worsening headache, particularly one that wakes you or comes with vision changes.
• Fainting, a racing or irregular heartbeat, or swelling in one leg.
• Thoughts of harming yourself, or depression or anxiety that interferes with daily life.

Two further situations deserve a doctor’s attention rather than a clinic’s dashboard. If you are already taking a medicine for blood pressure, cholesterol, diabetes, thyroid or mood, do not change or stop it because a longevity test or wearable suggests you should; bring the result to the prescriber. And if a longevity clinic has recommended an off-label or compounded medicine, a hormone without a confirmed deficiency, or a product labeled for research use, discuss it with your primary-care clinician before starting. The right answer may still be yes. It should be a yes reached with someone who has no stake in the sale and will follow you for years.

Prevention works best when it is boring, consistent and shared with a clinician who knows you. A longevity clinic can be part of that. It should never be a substitute for the doctor you call when something is actually wrong.

Frequently asked questions

What does a longevity clinic do?

A longevity clinic provides extended preventive-care visits, large laboratory panels, body-composition and fitness testing, sometimes imaging, and a follow-up plan aimed at extending healthy years. Some also prescribe medicines or hormones intended to slow aging. The evidence-backed portion is standard prevention: blood pressure, lipids, glucose, fitness, sleep and recommended screening. The experimental portion, such as biological-age tests and off-label drugs, has not been shown to lengthen life in humans.

Are longevity clinics worth it?

They can be worth it for people who lack consistent primary care and would benefit from an unhurried clinician who manages risk factors and coordinates screening. They are least likely to add value for already-healthy adults with normal labs, for whom extra testing mostly generates noise. The exotic services have no trial evidence for longer life. Judge a clinic by how much of its plan matches standard guidelines and how willing it is to recommend less.

Is there a longevity clinic in the USA?

Yes, longevity clinics operate in most large US metropolitan areas and increasingly in smaller cities, under names including longevity, precision, functional and executive health. Because no specialty board defines the field, offerings vary enormously from one practice to the next. Rather than searching for a nearby clinic, search for a clinician whose credentials you can verify and who will explain which recommendations are approved, which are off-label and which are unproven.

Is a longevity clinic covered by insurance?

Generally not as a whole. Insurance and Medicare cover guideline-recommended preventive services such as periodic visits, cholesterol and diabetes screening, age-appropriate cancer screening and adult vaccines, and some clinics bill those pieces. Membership fees, extended visit time, broad test panels without a diagnosis, whole-body imaging, epigenetic tests, IV infusions and off-label prescriptions are typically paid out of pocket. Ask the clinic to spell out exactly how the split works before your first visit.

Which longevity blood tests are actually worth doing?

A lipid panel, hemoglobin A1c, kidney and liver function, a complete blood count and thyroid testing form the core, and most adults can get them through routine care. Apolipoprotein B and a once-in-adulthood lipoprotein(a) measurement are endorsed by several cardiology societies for refining heart risk, and high-sensitivity CRP adds modest value. Broad micronutrient panels, food-sensitivity IgG tests and dozens of hormone measurements in healthy people mostly produce borderline results with no clear action.

Do biological age tests really work?

Epigenetic clocks are genuine research tools that predict mortality risk across large populations, but as individual products they have several years of measurement uncertainty and no trial showing that improving the number improves health. The advice that follows an “old” result is the same standard advice on sleep, exercise, blood pressure and lipids. Treat the result as a curiosity rather than a diagnosis, and never let it override risk factors your doctor can measure and modify.

Is rapamycin proven to slow aging in humans?

No. Rapamycin has repeatedly extended lifespan in genetically diverse mice in National Institute on Aging studies, which is why it attracts attention. Human research so far consists of small trials measuring immune markers and safety, not lifespan or disease. It is approved in the United States for transplant rejection and a rare lung condition; use for aging is off-label, carries known side effects, and any decision belongs with a treating clinician who has explained the uncertainty.

Should a healthy person get a full-body MRI?

No major screening guideline in the United States, United Kingdom or Europe recommends whole-body MRI for asymptomatic adults. The scan finds incidental abnormalities in a large share of people, most benign, leading to follow-up imaging, biopsies and anxiety without any demonstrated reduction in deaths. Targeted tests such as coronary calcium scoring in intermediate-risk adults or low-dose lung CT in eligible smokers answer specific questions and are supported by evidence.

What is the difference between a longevity clinic and a regular doctor?

The core medicine is the same; the difference is time, testing volume and add-ons. A longevity clinic typically offers longer visits, more laboratory markers, fitness and body-composition testing, and sometimes experimental interventions, paid largely out of pocket. A primary-care clinician delivers the guideline-backed prevention that has trial evidence, within insurance. The best outcome for most people is a primary-care relationship that functions well, with any longevity service sharing records rather than working in isolation.

What questions should I ask before joining a longevity clinic?

Ask the clinician’s board certification and specialty, what decision each extra test would change, how incidental imaging findings are handled, which proposed medicines are approved for the stated purpose and which are off-label or compounded, whether the clinic profits from products it recommends, how it coordinates with your existing doctor, and how it measures results beyond patient satisfaction. Clinics that welcome these questions tend to be the ones worth your time.

References

• National Institute on Aging – What Do We Know About Healthy Aging?
• National Institute on Aging – Interventions Testing Program (ITP)
• MedlinePlus – Health Screening
• NHS – NHS Health Check

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.